Skip to Main Content
Table 2.

Nrx-IV rescue experiments

% Defective segments
GenotypeStage 15Stage 17
Nrx-IV4304/Nrx-IV4304 93 (27/29) 90 (29/32) 
elav-Gal4/+; UAS-Nrx-IV/+; Nrx-IV4304/TM6 3 (1/34) 4 (1/28) 
elav-Gal4/+; UAS-Nrx-IV/+;Nrx-IV4304/Nrx-IV4304 22 (7/32) 83 (25/30) 
UAS-Nrx-IV/+; slit-Gal4 Nrx-IV4304/TM6 3 (1/33) 0 (0/30) 
UAS-Nrx-IV/+; slit-Gal4 Nrx-IV4304/Nrx-IV4304 92 (22/24) 96 (24/25) 
% Defective segments
GenotypeStage 15Stage 17
Nrx-IV4304/Nrx-IV4304 93 (27/29) 90 (29/32) 
elav-Gal4/+; UAS-Nrx-IV/+; Nrx-IV4304/TM6 3 (1/34) 4 (1/28) 
elav-Gal4/+; UAS-Nrx-IV/+;Nrx-IV4304/Nrx-IV4304 22 (7/32) 83 (25/30) 
UAS-Nrx-IV/+; slit-Gal4 Nrx-IV4304/TM6 3 (1/33) 0 (0/30) 
UAS-Nrx-IV/+; slit-Gal4 Nrx-IV4304/Nrx-IV4304 92 (22/24) 96 (24/25) 

Values in parentheses indicate the number of affected segments/total number of segments examined. MG migration was assayed using MG position, shape and anti-Wrapper staining. Additionally, in the slit-Gal4 experiments,anti-Nrx-IV staining identified MG expressing UAS-Nrx-IV. Homozygous Nrx-IV mutants were identified by the absence of Nrx-IV staining from the epidermis.

Close Modal

or Create an Account

Close Modal
Close Modal